

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Source of delay	Reasons for delay:	Comment
18/SC/0104	240005	EFFIP (E-support for Families and Friends of Individuals affected by Psychosis): A randomised controlled trial of a co-produced online intervention for carers	31/01/2018	09/03/2018	01/03/2018	16/04/2018	16/04/2018	16/04/2018	22/05/2018	Neither	F - No Eligible Patients Consented	Eligible patients screened and approached, but chose not to take part
16/HRA/5525	210175	MindSHINE 3: A definitive randomised controlled trial investigating two online wellbeing interventions to reduce NHS staff stress	30/01/2018	28/03/2018	28/01/2017	28/03/2018	05/04/2018	12/04/2018	16/04/2018			
16/NW/0888	213646	everyBody Plus – A randomised controlled trial using internet based guided self-help to bridge waiting time for face-to-face outpatient treatment for bulimia, binge eating disorder and other specified feeding and eating disorders (OSFED).	28/11/2017	05/04/2018	02/02/2018	05/04/2018	10/05/2018	10/05/2018	30/06/2018	Sponsor	D - Sponsor Delays	Sponsor submitted an amendment but didn't notify site

17/NW/0688	225304	Connecting People Implementation Study	09/04/2018	09/04/2018	13/02/2018	29/05/2018	04/06/2018	04/06/2018	02/07/2018	Sponsor	D - Sponsor Delays	Sponsor failed to provide draft Model Agreement along with document pack. Sponsor also made numerous changes to the Model Agreement, which delayed date site confirmed by sponsor and date site confirmed
18/SW/0037	240073	A feasibility study of eye-movement desensitization and reprocessing (EMDR) in people with an at-risk mental state (ARMS) for psychosis	27/02/2018	13/04/2018	13/04/2018	13/04/2018	23/05/2018	23/05/2018		Neither	F - No Eligible Patients Consented	Eligible patients identified and approached, but chose not to take part
18/SW/0043	239339	intEgrating Smoking Cessation treatment As part of routine Psychological care for dEpression (ESCAPE): a pragmatic randomised controlled, acceptability and feasibility trial	04/04/2018	24/05/2018	23/03/2018	24/05/2018	29/05/2018	29/05/2018	27/06/2018			
18/EM/0093	243516	A multicentre, multinational, randomised, double-blind, placebo-controlled,3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients with mild-moderateAlzheimer's Disease. ETHERAL Study	30/01/2018	27/07/2018	25/05/2018	01/08/2018	06/08/2018	06/08/2018	27/09/2018	Neither	F - No Patients Seen	Patients seen but screen failed

18/WA/0088	229419	A Phase 3, multicenter, randomized, double-blind, placebocontrolled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type	05/10/2017	16/08/2018	26/04/2018	27/07/2018	12/09/2018	12/09/2018	Neither	F - No Patients Seen	Patients seen but screen failed
------------	--------	---	------------	------------	------------	------------	------------	------------	---------	----------------------	---------------------------------
